Cargando…

2120. Minimum Inhibitory Concentration Distribution of Fluconazole against Cryptococcus Species and the Fluconazole Exposure Prediction Model

BACKGROUND: Fluconazole is lifesaving for the treatment and prevention of cryptococcosis; however, optimal dosing is unknown. Initial fluconazole doses of 100 mg to 2000 mg/day have been used. Prevalence of fluconazole non-susceptible Cryptococcus is increasing over time, risking the efficacy of lon...

Descripción completa

Detalles Bibliográficos
Autores principales: Chesdachai, Supavit, Rajasingham, Radha, Nicol, Melanie R, Meya, David, Bongomin, Felix, Abassi, Mahsa, Skipper, Caleb, Kwizera, Richard, Rhein, Joshua, Boulware, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809647/
http://dx.doi.org/10.1093/ofid/ofz360.1800
_version_ 1783462042103971840
author Chesdachai, Supavit
Rajasingham, Radha
Nicol, Melanie R
Meya, David
Bongomin, Felix
Abassi, Mahsa
Skipper, Caleb
Kwizera, Richard
Rhein, Joshua
Boulware, David
author_facet Chesdachai, Supavit
Rajasingham, Radha
Nicol, Melanie R
Meya, David
Bongomin, Felix
Abassi, Mahsa
Skipper, Caleb
Kwizera, Richard
Rhein, Joshua
Boulware, David
author_sort Chesdachai, Supavit
collection PubMed
description BACKGROUND: Fluconazole is lifesaving for the treatment and prevention of cryptococcosis; however, optimal dosing is unknown. Initial fluconazole doses of 100 mg to 2000 mg/day have been used. Prevalence of fluconazole non-susceptible Cryptococcus is increasing over time, risking the efficacy of long-established standard dosing. Based on current minimum inhibitory concentration (MIC) distribution, we modeled fluconazole concentration and area under the curve (AUC) relative to MIC to propose a rational fluconazole dosing strategy. METHODS: First, we conducted a systematic review using the MEDLINE database for reports of fluconazole MIC distribution against clinical Cryptococcus isolates. Second, we utilized fluconazole concentrations from 92 Ugandans who received fluconazole 800 mg/day coupled with fluconazole’s known pharmacokinetics to predict plasma fluconazole concentrations for doses ranging from 100 mg to 2000 mg via linear regression. Third, the fluconazole AUC above MIC ratio were calculated using Monte Carlo simulation and using the MIC distribution elucidated during the systemic review. RESULTS: We summarized 21 studies with 11,094 clinical Cryptococcus isolates. MICs were normally distributed with geometric mean of 3.4 mg/mL, median (MIC(50)) of 4 mg/mL, and 90th percentile (MIC(90)) of 16 mg/mL. The median MIC(50) trended upwards from 4 mg/mL in 2000–2012 to 8 mg/mL in 2014–2018. Predicted sub-therapeutic fluconazole concentrations (below MIC) would occur in 38% with 100 mg, 20% with 200 mg, and 8% with 400 mg. AUC/MIC ratio > 100 would occur in 53% for 400 mg, 74% for 800 mg, 84% for 1200 mg, and 88% for 1,600 mg. CONCLUSION: Currently recommended fluconazole doses may be inadequate for cryptococcosis. Further clinical studies are needed for rational fluconazole dose selection. [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6809647
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68096472019-10-28 2120. Minimum Inhibitory Concentration Distribution of Fluconazole against Cryptococcus Species and the Fluconazole Exposure Prediction Model Chesdachai, Supavit Rajasingham, Radha Nicol, Melanie R Meya, David Bongomin, Felix Abassi, Mahsa Skipper, Caleb Kwizera, Richard Rhein, Joshua Boulware, David Open Forum Infect Dis Abstracts BACKGROUND: Fluconazole is lifesaving for the treatment and prevention of cryptococcosis; however, optimal dosing is unknown. Initial fluconazole doses of 100 mg to 2000 mg/day have been used. Prevalence of fluconazole non-susceptible Cryptococcus is increasing over time, risking the efficacy of long-established standard dosing. Based on current minimum inhibitory concentration (MIC) distribution, we modeled fluconazole concentration and area under the curve (AUC) relative to MIC to propose a rational fluconazole dosing strategy. METHODS: First, we conducted a systematic review using the MEDLINE database for reports of fluconazole MIC distribution against clinical Cryptococcus isolates. Second, we utilized fluconazole concentrations from 92 Ugandans who received fluconazole 800 mg/day coupled with fluconazole’s known pharmacokinetics to predict plasma fluconazole concentrations for doses ranging from 100 mg to 2000 mg via linear regression. Third, the fluconazole AUC above MIC ratio were calculated using Monte Carlo simulation and using the MIC distribution elucidated during the systemic review. RESULTS: We summarized 21 studies with 11,094 clinical Cryptococcus isolates. MICs were normally distributed with geometric mean of 3.4 mg/mL, median (MIC(50)) of 4 mg/mL, and 90th percentile (MIC(90)) of 16 mg/mL. The median MIC(50) trended upwards from 4 mg/mL in 2000–2012 to 8 mg/mL in 2014–2018. Predicted sub-therapeutic fluconazole concentrations (below MIC) would occur in 38% with 100 mg, 20% with 200 mg, and 8% with 400 mg. AUC/MIC ratio > 100 would occur in 53% for 400 mg, 74% for 800 mg, 84% for 1200 mg, and 88% for 1,600 mg. CONCLUSION: Currently recommended fluconazole doses may be inadequate for cryptococcosis. Further clinical studies are needed for rational fluconazole dose selection. [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6809647/ http://dx.doi.org/10.1093/ofid/ofz360.1800 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Chesdachai, Supavit
Rajasingham, Radha
Nicol, Melanie R
Meya, David
Bongomin, Felix
Abassi, Mahsa
Skipper, Caleb
Kwizera, Richard
Rhein, Joshua
Boulware, David
2120. Minimum Inhibitory Concentration Distribution of Fluconazole against Cryptococcus Species and the Fluconazole Exposure Prediction Model
title 2120. Minimum Inhibitory Concentration Distribution of Fluconazole against Cryptococcus Species and the Fluconazole Exposure Prediction Model
title_full 2120. Minimum Inhibitory Concentration Distribution of Fluconazole against Cryptococcus Species and the Fluconazole Exposure Prediction Model
title_fullStr 2120. Minimum Inhibitory Concentration Distribution of Fluconazole against Cryptococcus Species and the Fluconazole Exposure Prediction Model
title_full_unstemmed 2120. Minimum Inhibitory Concentration Distribution of Fluconazole against Cryptococcus Species and the Fluconazole Exposure Prediction Model
title_short 2120. Minimum Inhibitory Concentration Distribution of Fluconazole against Cryptococcus Species and the Fluconazole Exposure Prediction Model
title_sort 2120. minimum inhibitory concentration distribution of fluconazole against cryptococcus species and the fluconazole exposure prediction model
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809647/
http://dx.doi.org/10.1093/ofid/ofz360.1800
work_keys_str_mv AT chesdachaisupavit 2120minimuminhibitoryconcentrationdistributionoffluconazoleagainstcryptococcusspeciesandthefluconazoleexposurepredictionmodel
AT rajasinghamradha 2120minimuminhibitoryconcentrationdistributionoffluconazoleagainstcryptococcusspeciesandthefluconazoleexposurepredictionmodel
AT nicolmelanier 2120minimuminhibitoryconcentrationdistributionoffluconazoleagainstcryptococcusspeciesandthefluconazoleexposurepredictionmodel
AT meyadavid 2120minimuminhibitoryconcentrationdistributionoffluconazoleagainstcryptococcusspeciesandthefluconazoleexposurepredictionmodel
AT bongominfelix 2120minimuminhibitoryconcentrationdistributionoffluconazoleagainstcryptococcusspeciesandthefluconazoleexposurepredictionmodel
AT abassimahsa 2120minimuminhibitoryconcentrationdistributionoffluconazoleagainstcryptococcusspeciesandthefluconazoleexposurepredictionmodel
AT skippercaleb 2120minimuminhibitoryconcentrationdistributionoffluconazoleagainstcryptococcusspeciesandthefluconazoleexposurepredictionmodel
AT kwizerarichard 2120minimuminhibitoryconcentrationdistributionoffluconazoleagainstcryptococcusspeciesandthefluconazoleexposurepredictionmodel
AT rheinjoshua 2120minimuminhibitoryconcentrationdistributionoffluconazoleagainstcryptococcusspeciesandthefluconazoleexposurepredictionmodel
AT boulwaredavid 2120minimuminhibitoryconcentrationdistributionoffluconazoleagainstcryptococcusspeciesandthefluconazoleexposurepredictionmodel